SCHEMBL2301208

SCHEMBL2301208

Cn1nccc1-c1c(Cl)sc(N)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PI4KA P42356 1/20 0.40
PIK3CG P48736 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
COMT P21964 1/20 0.38
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
S1PR1 P21453 1/20 0.35
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
ATM Q13315 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299249 0.69 ALDH1A1 (0.35) ALDH1A1MAPTKDM4ENPC1LMNA
SCHEMBL21858847 0.68 ALDH1A1 (0.48) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL15950989 0.67 COMT (0.60) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL31148036 0.65 ALDH1A1 (0.41) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL27002204 0.64 ALDH1A1 (0.43) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL30060833 0.63 CYP1A2 (0.46) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL16826278 0.62 CYP3A4 (0.53) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL17369090 0.62 CYP1A2 (0.53) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL29132897 0.62 COMT (0.46) ALDH1A1MAPTPIK3CDPIK3CAPIK3CB
SCHEMBL8121886 0.62 ALDH1A1 (0.45) ALDH1A1MAPTCOMTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592475-B2 Inhibitors of Akt activity GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
US-20110196009-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION 2011-08-11 US disclosed
US-20110196009-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION 2011-08-11 US disclosed
US-20110196009-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION 2011-08-11 US disclosed
WO-2010045309-A1 INHIBITORS OF AKT ACTIVITY GLAXOSMITHKLINE LLC (US) 2010-04-22 WO disclosed
WO-2010045309-A1 INHIBITORS OF AKT ACTIVITY GLAXOSMITHKLINE LLC (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196009-A1 INHIBITORS OF Akt ACTIVITY AKT2, AKT1, AKT3 ALDH1A1 3652/4885MAPT 4189/4885PIK3CD 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.